Seelos_full logo and icon color.jpg
Seelos Therapeutics to Host Key Opinion Leader Call to Discuss Phase I Data and Upcoming Trial Design for SLS-002
June 15, 2020 08:01 ET | Seelos Therapeutics, Inc.
NEW YORK, June 15, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders...
Seelos_full logo and icon color.jpg
Seelos Therapeutics to Host Key Opinion Leader Call to Discuss the Unmet Medical Needs in Suicide and Depression
May 19, 2020 09:01 ET | Seelos Therapeutics, Inc.
NEW YORK, May 19, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Provides Q1 2020 Business Update and Pipeline Developments
April 08, 2020 09:01 ET | Seelos Therapeutics, Inc.
NEW YORK, April 08, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Announces Additional Interim Data from Phase I Studies of Intranasal Racemic Ketamine (SLS-002)
February 26, 2020 08:01 ET | Seelos Therapeutics, Inc.
NEW YORK, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Operation Lifesaver introduces resource for news media reporting on suicide-related rail incidents
January 14, 2020 10:00 ET | Operation Lifesaver
Washington, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Operation Lifesaver, Inc., (OLI) the national, nonprofit rail safety education organization, is providing a new resource that offers effective messaging...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Announces Interim Data from Phase I Study of Intranasal Racemic Ketamine (SLS-002)
January 10, 2020 07:31 ET | Seelos Therapeutics, Inc.
NEW YORK, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Schedules Type C Meeting with FDA to Discuss Intranasal Racemic Ketamine Program (SLS-002)
January 06, 2020 08:02 ET | Seelos Therapeutics, Inc.
NEW YORK, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Logo-FullColour.png
Highmark Interactive to Launch Therapeutic Trials Using Software to Treat Concussion, Mental Health and More
December 05, 2019 09:10 ET | Highmark Interactive
TORONTO, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Highmark Interactive, an award-winning digital health company, is announcing their intention to begin therapeutic trials utilizing their FDA-cleared ‘EQ...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Announces Dosing of Phase I PK/PD Study of Intranasal Racemic Ketamine (SLS-002)
November 27, 2019 11:00 ET | Seelos Therapeutics, Inc.
NEW YORK, Nov. 27, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
New Report Reveals Worsening Disparities in Access to Behavioral Healthcare for Employer-Sponsored Health Plans   
November 20, 2019 10:16 ET | The Bowman Family Foundation
-Addiction Treatment Disparities for Inpatient, Outpatient Facility, and Office Visits are Stark Despite the National Opioid Crisis -Children’s Use of Out-of-Network Mental Health Office Visits is...